Rapport Therapeutics, Inc. reported significant successes in its clinical trial of RAP-219, leading to a dramatic stock increase.
Positive Results of RAP-219 Clinical Trial
The Phase 2a clinical trial of RAP-219 delivered impressive results with a 77.8% median reduction in clinical seizures over eight weeks (p=0.01). Importantly, 24% of participants achieved complete seizure freedom (p<0.0001).
The trial also met its primary endpoint, with 85.2% of patients achieving at least a 30% reduction in long episodes (LEs) compared to baseline (p<0.0001). These results hold particular significance given that up to 40% of patients with focal epilepsy continue to experience seizures despite existing therapies.
Stock Dynamics of Rapport Therapeutics
Following the announcement of positive trial results, Rapport Therapeutics stocks surged by 143.66%, reaching $34.99 in premarket trading on September 8, 2025. The previous closing price was $14.36.
Prior to this announcement, the company had been facing negative returns, reflecting a 19.05% year-to-date decline. The market capitalization stood at approximately $524 million before the surge, and analyst price targets averaged $34.20.
Future Prospects of RAP-219 and Company Plans
Rapport Therapeutics aims to meet with the FDA in Q4 2025 for an end-of-Phase 2 meeting and to initiate two pivotal Phase 3 trials in Q3 2026. Additional efficacy analyses and 8-week follow-up results are also expected in 2026.
In addition to epilepsy, the company is evaluating RAP-219 for bipolar mania and diabetic peripheral neuropathic pain, which could significantly expand the drug's target market.
The sharp rise in Rapport Therapeutics' stock following the successful trial results for RAP-219 highlights investor optimism regarding the company's future commercial success and new treatment for epilepsy patients.
